Status | Study |
Recruiting |
Study Name: Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis Condition: Scleroderma, Diffuse Diffuse Cutaneous Sy Date: 2015-06-30 Interventions: Drug: IVA337 Capsules of 200mg |
Active, not recruiting |
Study Name: Taking Charge of Systemic Sclerosis Condition: Scleroderma Date: 2015-05-22 Interventions: Other: Internet-based self-management program |
Recruiting |
Study Name: Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma Condition: Scleroderma Date: 2015-01-26 Interventions: Drug: atorvastatin Atorvastati |
Completed |
Study Name: Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial Condition: Systemic Scleroderma Date: 2015-01-18 Interventions: Drug: C-82 Topical Gel, 1% act |
Active, not recruiting |
Study Name: IVIG Treatment in Systemic Sclerosis Condition: Systemic Sclerosis Diffuse Scleroderma Date: 2013-01-28 Interventions: Biological: Privigen Subjects will receive 2 g/kg/mo of Privigen® for 6 months if randomized to the |
Completed |
Study Name: Morbidity and Mortality Follow Up for the Scleroderma Lung Study Condition: Scleroderma Date: 2013-01-04 Interventions: Other: Followup survey |
Completed |
Study Name: Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis Condition: Systemic Sclerosis Date: 2012-08-15 Interventions: Drug: Belimumab Belimumab (Benlysta®) decreases B-Cell survival and has been FDA approved for the t |
Recruiting |
Study Name: Scleroderma Registry & Repository at the Hospital for Special Surgery Condition: Scleroderma Date: 2012-08-01 |
Recruiting |
Study Name: Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis Condition: Scleroderma Date: 2012-06-18 Interventions: Drug: Campath Pediatric patients with dcSSc are eligible for the clinical trial if they fulfill the incl |
Recruiting |
Study Name: Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial Condition: Scleroderma Date: 2011-09-29 Interventions: Procedure: Cytoxan rATG/Fludarabine/HSCT |